https://cancer.holy-cross.com
Skip to Content
image description
  • image description
  • image description
  • image description

Cancer Clinical Trials

The Michael and Dianne Bienes Comprehensive Cancer at Holy Cross Hospital in Fort Lauderdale in Broward County (South Florida) offers an extensive panel of research studies, or clinical trials, to those battling breast cancer, colorectal cancer, lung cancer, melanoma (skin cancer), multiple myeloma (cancer of the plasma cells), leukemia (cancer of the blood cells) and other cancers. 

We also offer biomarker-driven trials for which the location of the tumor may not matter. Please scroll to learn more.

Advanced ER+/AR+ Breast Cancer

G200802

A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women.

For more information, contact Study Coordinator Eileen Georgi at 954-267-7748 or eileen.georgi@holy-cross.com.

Androgen Receptor-Positive Triple Negative Breast Cancer

G200901

A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+TNBC).

For more information, contact Study Coordinator Eileen Georgi at 954-267-7748 or eileen.georgi@holy-cross.com.

Biomarker-driven Trials (location of cancer may not matter)

CLDK378AUS23

Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module - 7 Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1.

For more information, contact Study Coordinator Mariana Lykoudis at 954-267-7792 or mariana.lykoudis@holy-cross.com.

 

Biomarker-driven Trials (location of cancer may not matter)

CBGJ398XUS04

Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations.

For more information, contact Study Coordinator Mariana Lykoudis at 954-267-7792 or mariana.lykoudis@holy-cross.com.

Breast - Metastatic, BRCA 1 and BRCA 2

Brocade 3 (M12-914)

A Phase 3 randomized placebo-controlled trial of carboplatin and paclitaxel with or without veliparib (ABT-888) in HER2-negative metastatirc or locally advanced unresectable BRCA-associated breast cancer.
www.Brocade3Study.com

For more information, contact Study Coordinator Eileen Georgi at 954-267-7748 or eileen.georgi@holy-cross.com.

Breast Registry

Nipple Sparing

ASBrS Nipple Sparing Mastectomy Registry.

For more information, contact Study Coordinator Eileen Georgi at 954-267-7748 or eileen.georgi@holy-cross.com

Breast – Early stage

neoMONARCH

A Phase 2 Neoadjuvant Trial Comparing the Biological Effects of 2 Weeks of Abemaciclib (LY2835219) in Combination with Anastrozole to those of Abemaciclib Monotherapy and Anastrozole Monotherapy and Evaluating the Clinical Activity and Safety of a Subsequent 14 Weeks of Therapy with Abemaciclib in Combination with Anastrozole in Postmenopausal Women with Hormone Receptor Positive, HER2 Negative Breast Cancer.

For more information, contact Study Coordinator Eileen Georgi at 954-267-7748 or eileen.georgi@holy-cross.com

Colorectal Cancer – Treatment experienced

A Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer.

For more information, contact Study Coordinator Tia Morgan at 954-229-8528 or tia.morgan@holy-cross.com.
 

 

Gastric – GEJ – Metastatic

EMR 100070-001

A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of avelumab (MSB0010718C) in subjects with metastatic or locally advanced solid tumors and expansion to selected indications.

For more information, contact Study Coordinator Mariana Lykoudis at 954-267-7792 or mariana.lykoudis@holy-cross.com.

Gastric – Metastatic

RAINFALL (I4T-MC-JVCU)

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin with or without Ramucirumab as First-line Therapy in Patients with Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. 

For more information, contact Study Coordinator Eileen Georgi at 954-267-7748 or eileen.georgi@holy-cross.com

Genetic Registry

City of Hope Registry

Molecular Genetics Studies of Cancer Patients and Their Relatives.

For more information, contact Genetic Counselor Carol Brudenell at 954-267-7704 or carol.brudenell@holy-cross.com.  

Lung – Early Stage

G029527

A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (ANTI−PD-L1 Antibody) Compared with best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in PD-L1−Selected Patients with Completely Resected Stage Ib−IIIa Non−Small Cell Lung Cancer.

For more information, contact Study Coordinator Mariana Lykoudis at 954-267-7792 or mariana.lykoudis@holy-cross.com

Lung – Metastatic

GO29437

A Phase III, Open-label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti−PD-L1 Antibody) in Combination with Carboplatin+Paclitaxel or Atezolizumab in Combination with Carboplatin+Nab-Paclitaxel versus Carboplatin+Nab-Paclitaxel in Chemotherapy-naive Patients with Stage IV Squamous Non−small Cell Lung Cancer.

For more information, contact Study Coordinator Kathy McTague at 954-267-7718 or kathleen.mctague@holy-cross.com 

Lung – Metastatic

G029436


A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti−Pd-L1 Antibody) in Combination with Carboplatin + Paclitaxel with or without Bevacizumab Compared with Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non−Small Cell Lung Cancer.

For more information, contact Study Coordinator Kathy McTague at 954-267-7718 or kathleen.mctague@holy-cross.com 

Melanoma

Keynote-252 / ECHO-301

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects with Unresectable or Metastatic Melanoma.

For more information, contact Study Coordinator Mariana Lykoudis at 954-267-7792 or mariana.lykoudis@holy-cross.com.


 

Pages

Three Women Photo

Cancer risk assessment, screening and prevention programs are vital to educating people about reducing their chances of developing cancer and assessing the need for intervention. Under the direction of our genetic nurse counselor and the Bienes Cancer Center physicians, our Cancer Risk and Prevention Program is for anyone with cancer or a family history of cancer. The vast majority of participants are women who have or have had breast or ovarian cancer, or are at high risk of developing these two cancers. Click to learn more about Genetic Counseling.

Cancer Resources

More Cancer Resources

®2005-2011 WebMD, LLC. All rights reserved.

WebMD does not provide medical advice, diagnosis or treatment.

See additional information.

Directions

image description